CRVS Stock Summary and Trading Ideas (Corvus Pharmaceuticals | NASDAQ:CRVS)

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals trades on the NASDAQ stock market under the symbol CRVS.

As of February 17, 2026, CRVS stock price declined to $17.84 with 829,503 million shares trading.

CRVS has a beta of 0.76, meaning it tends to be less sensitive to market movements. CRVS has a correlation of 0.01 to the broad based SPY ETF.

CRVS has a market cap of $1.49 billion. This is considered a Small Cap stock.

In the last 3 years, CRVS traded as high as $26.95 and as low as $.61.

The top ETF exchange traded funds that CRVS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

CRVS has outperformed the market in the last year with a return of +262.6%, while the SPY ETF gained +13.1%. In the last 3 month period, CRVS beat the market returning +123.0%, while SPY returned +1.8%. However, in the most recent 2 weeks CRVS has underperformed the stock market by returning -13.8%, while SPY returned -1.4%.

CRVS support price is $17.39 and resistance is $19.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVS shares will trade within this expected range on the day.